Unmet medical needs and therapeutic goals in the treatment of type 2 diabetes

Current Opinion in Investigational Drugs

Volumn 4, Issue 10, 2003, Pages 1173-1178

  Bessac, Laurence ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Drug evaluation; Novel targets; Therapeutic goals; Type 2 diabetes; Unmet needs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADIPOSE TISSUE; BRAIN; CELL FUNCTION; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EXERCISE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LIVER; LIVER TOXICITY; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SKELETAL MUSCLE; TREATMENT FAILURE; TREATMENT PLANNING;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 0242658606     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care (1998) 21(9):1414-1431.
2. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. J Am Med Assoc (1999) 281(14):1291-1297.
3. Haffner S: Coronary heart disease in patients with diabetes. N Engl J Med (2000) 342(14):1040-1042.
4. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. J Am Med Assoc (2000) 288(20):2579-2588. A summary of the theories and potential therapeutic interventions to prevent diabetic complications in the presence of hyperglycemia.
5. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group. Diabetic Med (1999) 16(9):716-730.
6. Strategies for care of the type 2 diabetic patient, excluding care of complications. Recommendations of ANAES (National Agency for Health Accreditation and Evaluation March 2000). Diabetes Metab (2000) 26(Suppl 5):10-96.
7. American Diabetes Association (ADA): Standards of medical care for patients with diabetes mellitus. Diabetes Care (2003) 27(Suppl 1):S33-S50.
8. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med (2002) 347(17):1342-1349. A good summary of the therapeutic manaagement of type 2 diabetes, including a discussion of the areas of uncertainty.
9. Mauvais-Jarvis F, Andreelli F, Hanaire-Broutin H, Charbonnel B, Girard J: Therapeutic perspectives for type 2 diabetes: Molecular and clinical insights. Diabetes Metab (2001) 27(4 Pt 1):415-423.
10. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J (2000) 321(7258):405-412.
11. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapy (UKPDS 49). The UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc (1999) 282(21):2005-2012.
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 352(9131):854-865.
13. American Diabetes Association: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care (2000) 23(Supl 1):S27-S31.
14. American Diabetes Association and National Institute of Diabetes Digestive and Kidney Diseases: The prevention or delay of type 2 diabetes. Diabetes Care (2002) 25(4):742-749.
15. Buchanan TA: Prevention of type 2 diabetes. What is it really? Diabetes Care (2003) 26(4):1306-1308.
16. Holman RR, Blackwell L, Manley SE, Tucker L, Frighi V, Stratton IM: Results from the Early Diabetes Intervention Trial. Diabetes (2003) 52(Suppl 1):A16.
17. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 348(5):383-393.
18. Shepherd PR, Kahn BB: Glucose transporters and insulin action - Implications for insulin resistance and diabetes mellitus. N Engl J Med (1999) 341(4):248-257. A comprehensive review of the physiology of glucose transport, possible causes of defects and therapeutic approaches.
19. Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature (2001) 414(6865):821-827.
20. Kahn SE: The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia (2003) 46(1):3-19. An excellent review of the critical role of β-cell dysfunction in type 2 diabetes.
21. Cerasi E, Boitard C, Efendic S, Ferrannini E, Henquin J-C, Steiner DF: The islet in type 2 diabetes: Back to the center stage. Diabetes (2001) 50(Suppl 1):S1-S3.
22. Efendic S, Boitard C, Cerasi E, Ferrannini E, Henquin J-C, Steiner DF: Regulation of insulin production. In search of therapeutic targets. Diabetes (2002) 51(Suppl 3):S285-S287. The editorial to a special issue focused on the search of therapeutic targets for the regulation of insulin secretion.
23. Link JT: Pharmacological regulation of hepatic glucose production. Curr Opin Invest Drugs (2003) 4(4):421-429.
24. Staehr P, Hother-Nielsen O, Beck-Nielsen H: Hepatic glucose production: Therapeutic target in type 2 diabetes? Diabetes Obesity Metab (2002) 4(4):215-223. A balanced overview of updated knowledge, including drug targets.
25. Laborde E, Manchem VP: Small molecule activators of the insulin receptor: Potential new therapeutic agents for the treatment of diabetes mellitus. Curr Med Chem (2002) 9(24):2231-2242.
26. Khan AH, Pessin JE: Insulin regulation of glucose uptake: A complex interplay of intracellular signalling pathways. Diabetologia (2002) 45(11):1475-1483. An update on intracellular insulin signaling pathways.
27. Wheatcroft SB, Williams IL, Shah AM, Kearney MT: Pathophysiological implications of insulin resistance on vascular endothelial function. Diabetic Med (2003) 20(4):255-268. A good summary of the mechanisms underlying both insulin resistance and endothelial dysfunction, including therapeutic options.
28. Musi N, Goodyear LJ: Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metabol Disord (2002) 2(2):119-127.
29. Sambandam GD, Lopaschuk GD: AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog Lipid Res (2003) 42(3):238-256.
30. Muller G, Frick W: Signalling via caveolin: Involvement in the cross-talk between phosphoinositolglycans and insulin. Cell Mol Life Sci (1999) 56(11-12):945-970.
31. Giannoukakis N, Robbins PD: Gene and cell therapies for diabetes mellitus: Strategies and clinical potential. BioDrugs (2002) 16(3):149-173.
32. Shafrir E, Raz I: Diabetes: Mellitus or lipidus? Diabetologia (2003) 46(3):433-440. The role of fat metabolism reconsidered versus the usual emphasis on the glucose-insulin axis.
33. Greensberg AS, McDaniel ML: Identifying the links between obesity, insulin resistance and β-cell function: Potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest (2002) 32(Suppl 3):24-34.
34. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G: Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J (2002) 16(10):1163-1176.
35. Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG: Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol (2003) 28(2):87-102.
36. Muzumdar R, Ma X, Yang X, Atzmon G, Bernstein J, Karkanias G, Barzilai N: Physiologic effect of leptin on insulin secretion is mediated mainly through central mechanisms. FASEB J (2003) 17(9):1130-1132.
37. Kyriaki G: Brain insulin: Regulation, mechanisms of action and functions. Cell Mol Neurobiol (2003) 23(1):1-25.
38. Obici S, Zhang BB, Karkanias G, Rossetti L: Hypothalamic insulin signalling is required for inhibition of glucose production. Nat Med (2002) 8(12):1376-1382.
39. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH: Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes (2003) 52(3):812-817.
40. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G: Low-grade systemic inflammation and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes (2003) 52(7):1799-1805.
41. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signalling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes (2003) 52(1):1-8.
42. European Agency for the Evaluation of Medicinal Products: Note for Guidance of Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus. London, UK (2002):CPMP/EWP/1080/00.
43. Nash DB, Koening JB, Novielli KD, Liberoni R, Reisman M: The importance of individualized pharmaceutical therapy in the treatment of diabetes mellitus. Disease Management (2001) 4(Suppl 1):S5-S23. A comprehensive overview of the reasons why the treatment of type 2 diabetes should be better patient-tailored.
44. Soltész G; Diabetes in the young: A paediatric and epidemiological perspective. Diabetologia (2003) 46(4):447-454.
45. Steinberger J, Daniels SR: Obesity, insulin resistance, diabetes, and cardiovascular risk in children. An American Heart Association Scientific Statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation (2003) 107(10):1448-1453.
46. Goran MI, Ball GD, Cruz ML: Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescent. J Clin Endocrinol Metab (2003) 88(4):1417-1427.
47. Sinclair AJ, Meneilly GS: Re-thinking metabolic strategies for older people with type 2 diabetes mellitus: Implications of the UK Prospective Diabetes Study and other recent studies. Age Ageing (2000) 29(5):393-397.
48. Rosenstock J: Management of type 2 diabetes mellitus in the elderly: Special considerations. Drugs Aging (2001) 18(1):31-44.
49. Clark CM, Fradkin JE, Hiss RG, Lorenz RA, Vinicor F, Warren-Boulton E: Promoting early diagnosis and treatment of type 2 diabetes: The National Diabetes Education Program. J Am Med Assoc (2000) 284(3):363-365.
50. Yki-Jarvinen H: Management of type 2 diabetes mellitus and cardiovascular risk: Lessons from intervention trials. Drugs (2000) 60(5):975-983.
51. Fisher M: Diabetes: Can we stop the time bomb? Heart (2003) 89(Suppl 2):28-30.
52. Mooradian AD: Cardiovascular disease in type 2 diabetes mellitus: Current management guidelines. Arch Intern Med (2003) 163(1):33-40.
53. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. Br Med J (2003) 326(7404):1419.